Irbesartan did not reduce cardiovascular events in patients with atrial fibrillation. (Funded by Bristol-Myers Squibb and Sanofi-Aventis; ClinicalTrials.gov number, NCT00249795.).
S Yusuf, JS Healey, J Pogue, S Chrolavicius, M Flather, RG Hart, SH Hohnloser, CD Joyner, MA Pfeffer, SJ Connolly
Research output: Contribution to journal › Article › peer-review